Sex, age, primary tumor localization, disease status, metastasis site, KRAS mutation status, CEA level at diagnosis, Bevacizumab setting, and the chemotherapy schemes administered with bevacizumab are shown in Table 2. Here, KRAS is linked to neoplasm.